news
Pfizer acquires Alacer Corp.
27 February 2012 | By Pfizer
Maker of Emergen-C®, #1 U.S. Vitamin C brand, expands Pfizer’s vitamin and dietary supplement business...
List view / Grid view
Pfizer
news
Pfizer statement regarding CDC’s ACIP discussion of Prevnar 13®
22 February 2012 | By Pfizer
Pfizer believes Prevnar 13 should be recommended for all adults 50 years of age and older...
news
Pfizer and Hisun announce progress on potential joint venture to increase access to high quality branded generic medicines
17 February 2012 | By Pfizer
The framework agreement builds upon the MOU, and is an important milestone in the formation of a joint venture between the two companies...
news
FDA accepts Pfizer’s New Drug Application for Tafamidis Meglumine
15 February 2012 | By Pfizer
A novel, investigational treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)...
news
Private and public partners unite to combat 10 neglected tropical diseases by 2020
30 January 2012 | By
Partners pledge innovative, coordinated action aimed at new WHO goals...
news
Pfizer announces FDA acceptance of New Drug Application for Bosutinib
27 January 2012 | By Pfizer
The U.S. FDA has accepted its NDA for standard review of bosutinib...
news
U.S. Food and Drug Administration approves Pfizer’s INLYTA® (axitinib)
27 January 2012 | By Pfizer
First treatment to demonstrate superior benefit in a Phase 3 study compared with another targeted agent in advanced RCC...
news
Medivation and Pfizer announce results from Phase 3 Concert trial of dimebon in Alzheimer’s disease
17 January 2012 | By Pfizer
Dimebon did not meet primary efficacy endpoints...
news
SFJ Pharma Ltd. II announces agreement with Pfizer to develop Axitinib
9 January 2012 | By Citigate Dewe Rogerson
SFJ announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial...
news
Pfizer receives FDA approval to extend use of Prevnar 13®
30 December 2011 | By Pfizer
First pneumococcal conjugate vaccine for adults 50+ has potential to help address high incidence of pneumococcal pneumonia...
news
Pfizer reports positive results from Phase 3 trial Of Lyrica (pregabaline)
19 December 2011 | By Pfizer
Patients with Restless Legs Syndrome (RLS) show significant benefit...
article
Drug discovery leaders roundtable
13 December 2011 | By Andrew A. Parsons, Vice President Preclinical Drug Development, GlaxoSmithKline and Steve Street, Vice President, Head of Research Centres of Emphasis, Head of WRD Continuous Improvement, Pfizer and William Strohl, Vice President of Biologics Research, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development and Eckhard von Keutz, Senior Vice President, Head Global Early Development, Bayer HealthCare
External economic pressures have been identified as the major driver for the pharmaceutical outsourcing market. Over and above the fiscal advantages of adopting this strategy, what other benefits and indeed risks do you see associated with this approach? Steve Street: We definitely began our out - sourcing efforts based on…
news
Pfizer elects CEO Ian Read as Chairman of the Board
12 December 2011 | By Pfizer
Pfizer Inc. has announced that its Board of Directors has elected Ian Read, as Chairman of the Board and CEO, effective immediately...
news
Pfizer completes acquisition of Excaliard
2 December 2011 | By Pfizer
Pfizer Inc. have announced that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company...
news
Pfizer completes acquisition of Ferrosan Consumer Health’s Business
1 December 2011 | By Pfizer
Pfizer Inc. have announced that it has completed its previously announced acquisition of Ferrosan Consumer Health’s business...
